




PATENT  
Docket No. 28967/34140A

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

U.S. Applicants: Alitalo, K., et al,	)	<b>Allowed: September 26, 2003</b>
Serial No.: 09/534,376	)	Express Mail Label No. EV233435853US
Filed: March 24, 2000	)	I hereby certify that this paper and the
For: Vascular Endothelial Growth	)	documents referred to as enclosed
Factor C (VEGF-C) Protein	)	herewith are being deposited with the
and Gene, Mutants Thereof,	)	United States Postal Service "Express
and Uses Thereof	)	Mail Post Office to Addressee" Service
	)	Under 37 C.F.R. §1.10 on the date
	)	indicated and are addressed to:
Examiner: Eileen B. O'Hara	)	Mail Stop Issue Fee, Commissioner for
	)	Patents, P.O. Box 1450, Alexandria,
	)	Virginia 22313-1450, on this date:
Group Art Unit: 1646	)	December 23, 2001
	)	
	)	Richard Zimmermann

**TERMINAL DISCLAIMER**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Licentia Ltd., and Ludwig Institute for Cancer Research are each the owner of 50% interest in the above-captioned application and in second application serial number 09/631,092, filed on August 2, 2000. The owner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term of any prior patent issuing on said second application, including any patent term extensions, restorations or adjustments for said patent issuing on said second application available under all applicable statutes including 35 U.S.C. §§ 154 through 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent issuing on said second application. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and

during such period that the legal title to it and to any prior patent issuing on said second application shall be commonly owned. This agreement runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent issuing on said second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that the patent issuing on said second application expires for failure to pay a maintenance fee, is held unenforceable and/or invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or its term is in any manner shortened prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.


This Terminal Disclaimer is accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300  
(312) 474-0448 (Telefacsimile)


Date: December 23, 2003

  
\_\_\_\_\_  
David A. Gass  
Registration No. 38,153



PATENT  
Docket No. 28967/34140A

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

U.S. Applicants: Alitalo, K., et al,	) <b>Allowed: September 26, 2003</b>
Serial No.: 09/534,376	)
Filed: March 24, 2000	) Express Mail Label No.: EV233435853US
For: Vascular Endothelial Growth	)
Factor C (VEGF-C) Protein	) I hereby certify that this paper and the
and Gene, Mutants Thereof,	) documents referred to as enclosed herewith
and Uses Thereof	) are being deposited with the United States
	) Postal Service "Express Mail Post Office to
	) Addressee" Service Under 37 C.F.R. §1.10
	) on the date indicated and are addressed to:
	) Mail Stop Issue Fee, Commissioner for
Examiner: Eileen B. O'Hara	) Patents, P.O. Box 1450, Alexandria, Virginia
	) 22313-1450, on December 23, 2001
Group Art Unit: 1646	)
	)
	) 
	) Richard Zimmermann

**TRANSMITTAL OF TERMINAL DISCLAIMER**

Mail Stop Issue Fee  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:


Sir:

For consistency, the Applicants have submitted herewith a terminal disclaimer relative to co-owned U.S. Patent Application Serial No. 09/631,092. This application is already tied to the '092 application because terminal disclaimers have been filed in both cases relative to the same related patent, U.S. Patent No. 6,361,946. In view of these facts, it is believed that this disclaimer has no further effect on the statutory term of this application, and it is not intended as an admission that any double patenting allegations have merit.

Respectfully submitted,  
MARSHALL, GERSTEIN & BORUN LLP  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300  
(312) 474-0448 (Telefacsimile)

Date: December 23, 2003

By:

  
David A. Gass  
Registration No. 38,153